In 217 adults with resistant hypertension, baxdrostat 2 mg added to background therapy lowered 24 h ambulatory systolic BP by 14·0 mm Hg more than placebo at 12 weeks (n=184 analysed). Potassium >6 mmol/L occurred in 3% vs 0%.
RCTn = 217
Azizi et al. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial